Mural Oncology to be acquired by XOMA unit for up to $2.24/share in cash

* Mural Oncology (NASDAQ:MURA [https://seekingalpha.com/symbol/MURA]) and XOMA Royalty (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]) have entered [https://seekingalpha.com/pr/20206473-mural-oncology-announces-entry-into-agreement-to-be-acquired-by-xra-5-corp-a-wholly-owned] into a definitive agreement under which XRA 5, a newly formed company wholly owned by XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural for cash.
* Under the terms of the acquisition, each Mural shareholder would receive a base cash price of $2.035 per share and may receive an additional cash amount per share of up to $0.205.
* Following a strategic review process, the Mural board of directors determined the acquisition and cash offer by XOMA Royalty is in the best interests of all Mural shareholders and has approved the acquisition.
* The deal has also been approved by the boards of directors of XOMA Royalty and Sub.
* The acquisition, excluding any amount that may be payable in respect of the additional price per share, values the entire issued and to be issued share capital of Mural at approximately $36.2 million.

MORE ON MURAL ONCOLOGY, XOMA

* I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals [https://seekingalpha.com/article/4809382-xoma-royalty-i-staying-neutral-stock-after-lava-hillevax-deals]
* XOMA Royalty to acquire cancer drug developer LAVA Therapeutics [https://seekingalpha.com/news/4477180-lava-therapeutics-stock-gains-ma-deal-with-xoma]
* Turnstone Biologics to be acquired by XOMA Royalty [https://seekingalpha.com/news/4463228-turnstone-biologics-acquired-xoma-royalty]
* Seeking Alpha’s Quant Rating on Mural Oncology [https://seekingalpha.com/symbol/MURA/ratings/quant-ratings]
* Historical earnings data for Mural Oncology [https://seekingalpha.com/symbol/MURA/earnings]